MEDICAL ADVOCATES
WOMEN AND HIV RESOURCE CENTER
  ARV/HAART Pregnancy Studies  
General Studies              Protease Inhibitors
 Treatment Guidelines     Nucleoside Analogues             
Safety and Efficacy          NNRTIs 
Tolerability                          
Resistance
Therapeutic Drug Monitoring
Immune Status
Adverse Events
 Outcome Studies
Adherence
Discontinuation of ARVs
ARVs and Vaginal Delivery
 ARVs and C-Sections
 Treatment of Neonates

 
HIV Pregnancy Main Page Women Main Page  
Last Update:  August 04, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Studies/Reports
 
           Journal Papers, Abstracts, and Commentaries
 
 
Increased mtDNA Levels Without Change in Mitochondrial Enzymes in Peripheral Blood Mononuclear
Cells of Infants Born to HIV-Infected Mothers on Antiretroviral Therapy.
 McComsey GA, Kang M, Ross AC, et al
HIV Clin Trials. 2008 Jan 1;9(2):126-136.
 Abstract

Immunologic features of HIV-1-infected women on HAART at delivery.
Ono E, Dos Santos AM, Machado DM, et al
Cytometry B Clin Cytom. 2008 Apr 7 ||
 Abstract
 
Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in
HIV-exposed, uninfected newborn infants.
El Beitune P, Duarte G, Campbell O, et al
Braz J Infect Dis. 2007 Jun;11(3):314-7.
 Abstract
 
ARTICLE
Characteristics and management of HIV-1-infected pregnant women enrolled in a
randomised trial: differences between Europe and the USA.
Newell ML, Huang S, Fiore S, et al   
BMC Infect Dis. 2007 Jun 20;7(1):60
 Paper
 
A WEEK-IN-REVIEW FEATURED REPORT
Time to undetectable viral load after highly active antiretroviral therapy initiation among
HIV-infected pregnant women.
European Collaborative Study; Patel D, Cortina-Borja M, Thorne C, Newell ML.
Clin Infect Dis. 2007 Jun 15;44(12):1647-56.
 Abstract
 
AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy
and management of obstetric, anesthetic, and pediatric issues.
Rigopoulos D, Gregoriou S, Paparizos V, Katsambas A.
Skinmed. 2007 Mar-Apr;6(2):79-84
 Abstract
 
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Volmink J, Siegfried N, van der Merwe L, Brocklehurst P.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510.
 Abstract
 
A Prospective Controlled Study of Neurodevelopment in HIV-Uninfected Children Exposed to
Combination Antiretroviral Drugs in Pregnancy.
Alimenti A, Forbes JC, Oberlander TF, et al
Pediatrics. 2006 Aug 28;
 Abstract
 
Longitudinal Relationships Between Use of Highly Active Antiretroviral Therapy and
Satisfaction With CareAmong Women Living With HIV/AIDS.
Burke-Miller JK, Cook JA, Cohen MH, et al
Am J Public Health. 2006 May 2;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Failure to eradicate HIV despite fully successful HAART initiated in the first days of life.
Vigano A, Trabattoni D, Schneider L,
Pediatr. 2006 Mar;148(3):389-91.
Abstract

Highly Active Antiretroviral Therapy Started during Pregnancy or Postpartum Suppresses
HIV-1 RNA, but Not DNA, in Breast Milk.
 Shapiro RL, Ndung'u T, Lockman S, et al  Infect Dis. 2005 Sep 1;192(5):713-9.
Abstract
 
Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women.
 Beitune PE, Duarte G, Foss MC, Montenegro RM Jr, et al 
Diabetes Metab Res Rev. 2005 Jul 15; 
Abstract 
 
Antiretroviral therapy and pregnancy
Wunder D, Evison JM.   
Ther Umsch. 2005 Jan;62(1):37-42
 Abstract 
 
Mother-to-Child Transmission of HIV Infection in the Era of Highly Active
Antiretroviral  Therapy.
European Collaborative Study.
Clin Infect Dis. 2005 Feb 1;40(3):458-465
 Abstract 
 
Decrease in Hospitalization and Mortality Rates among Children with Perinatally
Acquired HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy.
Viani RM, Araneta MR, Deville JG, Spector SA. et al
Clin Infect Dis. 2004 Sep 1;39(5):725-31.
 Abstract 

FULL-TEXT ARTICLE
 Women's reasons for not participating in follow up visits before starting short
course antiretroviral prophylaxis for prevention of mother to child transmission
of HIV: qualitative interview study
Painter TM, Diaby KL, Matia DM, et al 
BMJ  2004;329:543
 Paper

Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding:
from animal studies to randomized clinical trials.
Gaillard P, Fowler MG, Dabis F, et al   
J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):178-87.
 Abstract 

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.
 Safrit JT, Ruprecht R, Ferrantelli F, et al   
J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):169-77.
Abstract
 
Decision analysis to guide choice of interventions to reduce mother-to-child
transmission of HIV.
Bertolli J, Hu DJ, Nieburg P, et al.
AIDS. 2003 Sep 26;17(14):2089-98.
 Abstract
 
Human immunodeficiency virus and pregnancy.
 Kotler DP.
 Gastroenterol Clin North Am 2003 Mar;32(1):437-48,
Abstract
 
Antiretroviral therapy in HIV-infected pregnant women and their infants: current
interventions and challenges.
 Shannon M.
J Perinat Neonatal Nurs 2002 Sep;16(2):1-25
Abstract
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV
infection (Cochrane Review).
 Brocklehurst P, Volmink J.  
 Cochrane Database Syst Rev 2002;(1):CD003510
Abstract
 
          Conference Reports, Abstracts, and Posters
 
 
Impact of HAART on reducing mortality of HIV+ pregnant women (PW) with advanced
HIV disease in the setting of PMTCT
 Deschamps MM, Bonhomme J, Marcelin A,  et al
 (4th IAS Conference)
 Abstract

POSTER
Resistance Mutation Patterns in Plasma and Breast Milk of HIV-infected Women Receiving
HAART for PMTCT: A Study within the DREAM Program
M Giuliano, G Guidotti, M Andreotti, et al
 (14  CROI)
PDF Poster    Abstract

Effect of ART Regimens on Selected Hematologic and Hepatic Parameters of HIV-1-
uninfected African Infants
T Taha, G Kafulafula, Q Li, et al
(14 CROI)
 Abstract
Safety and Efficacy
 
          Journal Papers, Abstracts, and Commentaries
 
 
Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels,
 and anthropometric parameters of their neonates.
 El Beitune P, Duarte G, Machado AA, et al 
Clinics. 2005 Jun;60(3):207-212.
Abstract
 
The safety of antiretroviral drugs in pregnancy.
Thorne C, Newell ML.
Expert Opin Drug Saf. 2005 Mar;4(2):323-35. R
 Abstract

Simplified antiviral prophylaxis with or and without artificial feeding to reduce
mother-to-child transmission of HIV in low and middle income countries:
modelling positive and negative impact on child survival.
Walley J, Witter S, Nicoll A.
Med Sci Monit 2001 Sep;7(5):1043-1051
 Abstract

Antiretroviral therapy in pregnancy: a focus on safety.
Taylor GP, Low-Beer
N.Drug Saf 2001;24(9):683-702
 Abstract

The efficacy and tolerability of combination antiretroviral therapy in pregnancy:
infant andmaternal outcome.
Clarke SM, Mulcahy F, Healy CM, Condon S, Butler K.
Int J STD AIDS 2000 Apr;11(4):220-3
Abstract

Antiretroviral therapies in pregnancy: maternal, fetal and neonatal  effects.
Swiss HIV CohortStudy, the Swiss Collaborative HIV and Pregnancy Study,
and the Swiss Neonatal HIV Study. 
Lorenzi P, Spicher VM, Laubereau B, Hirschel B, et al.
AIDS 1998 Dec 24;12(18):F241-7 
Abstract

 		 
          Conference Reports, Abstracts, and Posters
 
 
Highly active antiretroviral therapy (HAART) in pregnant HIV-infected women.
Efficacy and safety for the mothers and infants
B Vandercam, M Dupont, F Abarzua
(15IAC)
 Abstract
 
Optimal HAART in pregnant women with multi-drug resistant virus
J Gilmore, J R Kostman
 (15IAC)
 Abstract
 
ANTIRETROVIRAL TREATMENT IN HIV-INFECTED PREGNANT WOMEN:
EFFICACY, SAFETY AND IMPACT ON DURATION OF PREGNANCY
A. Maccabruni, G. Bossi, M.F. Ravagni Probizer, A. Moretti
 (2nd IAS)
 Abstract

Report of Results of PACTG 316: An International Phase III Trial of Standard
Antiretroviral (ARV) Prophylaxis plus Nevirapine (NVP) for Prevention of 
Perinatal HIV Transmission
(8 CROI)  
Abstract

  
Tolerability
 
          Journal Papers, Abstracts, and Commentaries
 
  The efficacy and tolerability of combination antiretroviral therapy in pregnancy
infant and maternal outcome
Clarke SM, Mulcahy F, Healy CM, Condon S, Butler KM
Int J STD AIDS 2000
Abstract
Immune Status
 
          Journal Papers, Abstracts, and Commentaries
 
  Immune Status and Uptake of Antiretroviral Interventions to Prevent
Mother-to-Child Transmission of HIV-1 in Africa.
For the ANRS 1201/1202 Ditrame Plus Study Group.
J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):755-757.
 Abstract
Resistance
 
            Journal Papers, Abstracts, and Commentaries 
                       
 
Time Trends for HIV-1 Antiretroviral Resistance Among Antiretroviral-Experienced and -Naive
Pregnant Women in New York City During 1991 to Early 2001.
Welles SL, Bauer GR, Larussa PS, et al
J Acquir Immune Defic Syndr. 2006 Dec 14
 Abstract
 
Emergence of antiretroviral resistance in HIV-positive women receiving
combination antiretroviral therapy in pregnancy.
Lyons FE, Coughlan S, Byrne CM, et al
AIDS. 2005 Jan 3;19(1):63-67.
 Abstract

Mother-to-child transmission of drug-resistant HIV. 
Kijak GH, Avila MM, Salomon H.
 Drug Resist Updat 2001 Feb;4(1):29-37
 Abstract
The role of antiretrovirals and drug resistance in vertical transmission of
HIV-1 infection.
Brenner BG, Wainberg MA
Ann N Y Acad Sci 2000 Nov;918:9-15 
Abstract

  

          Conference Reports, Abstracts, and Posters

 
Different development of HIV drug resistance mutation patterns in Subtype 06_cpx after
mother-to-child transmission
 M Stürmer, A Carlebach, S Staszewski
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract 

Prevalence of Genotypic Drug Resistance in HIV-Infected Newborns in New
York State
M. Parker, N. Wade, B. K. Gallagher, et al.
(9RETRO)
 Abstract

Selection of Resistance Mutations in Pregnant Women Receiving Short-Course
AntiretroviralRegimens with ZDV and 3TC to Prevent Perinatal Transmission (PETRA
Study)
M. Giuliano, T. Galluzzo, R. Amici, et al.
 (9RETRO)
 Abstract

  
Therapeutic Drug Monitoring
 
          Journal Papers, Abstracts, and Commentaries
 
  Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.
 Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F.
Br J Clin Pharmacol. 2008 Jun 4.
 Abstract
Outcome Studies
 
            Journal Papers, Abstracts, and Commentaries 
 
  Improved Obstetric Outcomes and Few Maternal Toxicities Are Associated
With Antiretroviral Therapy, Including Highly Active Antiretroviral Therapy
During Pregnancy.
Tuomala RE, Watts DH, Li D, et all  
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):449-473
 Abstract

          Conference Reports, Abstracts, and Posters

 
Pregnancy Outcome in HIV-1-infected Women Receiving Combination
Therapy Prior to Conception
E Machado, C Hofer, S Nogueira, et al.
 (12 CROI)
 Abstract

Role of Combination Antiretroviral Therapy and Mode of Delivery in Perinatal
HIV Transmission (PHT), Pediatric Spectrum of Disease Project (PSD), United
States, 1995-2000
J. Patel, S. Melville, C. Heath, et al.
(9 CROI
 Abstract

  
   
ARVs and Vaginal Delivery
 
          Journal Papers, Abstracts, and Commentaries
 
  The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly
active antiretroviral therapy and a policy of vaginal delivery.
Boer K, Nellen JF, Patel D, et al  BJOG. 2007 Feb;114(2):148-55.
Abstract
 Adherence
 

          Conference Reports, Abstracts, and Posters

 
Adherence to Antiretrovirals Among US Women During and After Pregnancy.
 Bardeguez AD, Lindsey JC, Shannon M, et al 
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):408-417.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.
Mellins CA, Chu C, Malee K, et al
AIDS Care. 2008 Jun 17:1-11.
 Abstract
 
Adherence to Antiretrovirals Among US Women During and After Pregnancy.
 Bardeguez AD, Lindsey JC, Shannon M 
J Acquir Immune Defic Syndr. 2008 Jul 8.
 Abstract
 
Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral
therapy in pregnancy: adherence analysis a5084.
Cohn SE, Umbleja T, Mrus J, et al 
AIDS Patient Care STDS. 2008 Jan;22(1):29-40.
 Abstract

A Prospective Cohort Study of HIV-1-infected Pregnant Women and Their Infants
in Latin America and the Caribbean: The NICHD International Site Development
Initiative Perinatal Study
J Read, P Cahn, M Losso, et al
(12 CROI)
 Abstract
Discontinuation of ARVs
 

          Conference Reports, Abstracts, and Posters

  Immunological dynamics after delivery in HIV-infected pregnant
women who discontinued combined antiretroviral use
R Palacios, J F Senise, Z N Tanno, et al
(15IAC)
 Abstract
Treatment of Neonates
 
          Journal Papers, Abstracts, and Commentaries
 
  Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine,
nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected
children: week 24 results of a randomized controlled trial--PACTG 377.
Pediatric AIDS Clinical Trials Group 377 Study Team.
Wiznia A, Stanley K, Krogstad P, et al.
AIDS Res Hum Retroviruses 2000 Aug 10;16(12):1113-21
Abstract
 
Protease Inhibitors
 

          Journal Papers, Abstracts, and Commentaries

 
Protease Inhibitor Therapy and Fetal Growth Potential in HIV-Positive Women.
 Iqbal S, Kriebs J, Harman C, et al 
Am J Perinatol. 2008 May 28.
 Abstract

Lipids and Lactate in Human Immunodeficiency Virus-1 Infected Pregnancies With
or Without Protease Inhibitor-Based Therapy.
 Livingston EG, Cohn SE, Yang Y, et al
Obstet Gynecol. 2007 Aug;110(2):391-397.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS
Clinical Trials Group A5084.
Hitti J, Andersen J, McComsey G, et al  
Am J Obstet Gynecol. 2007 Apr;196(4):331.e1-7.
 Abstract
 
Protease Inhibitor Use in 233 Pregnancies.
 Morris AB, Dobles AR, Cu-Uvin S, 
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):30-33.
 Abstract
 
The impact of protease inhibitors on maternal serum screening analyte levels
in pregnant women who are HIV positive.
Einstein FH, Wright RL, Trentacoste S, et al
Am J Obstet Gynecol. 2004 Sep;191(3):1004-8.
 Abstract

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in
pregnant women who are infected with human immunodeficiency virus.
Chappuy H, Treluyer JM, Rey E, et  al
Am J Obstet Gynecol. 2004 Aug;191(2):558-62.
 Abstract
 
Insulin resistance complicating pregnancy in a human immunodeficiency virus-
infected patient treated with protease inhibitors and corticosteroids.
Aschkenazi S, Rochelson B, Bernasko J, Kaplan J.
Obstet Gynecol. 2003 Nov;102(5 Suppl):1210-2.
Abstract

Concentrations of protease inhibitors in cord blood after in utero exposure.
Mirochnick M, Dorenbaum A, Holland D,  
Pediatr Infect Dis J 2002 Sep;21(9):835-8
 Abstract
 
Protease Inhibitors and Decreased Birth Weight in HIV-Infected Pregnant Women
With Impaired Glucose Tolerance
 Chmait R, Franklin P, Spector SA, et al .
J Perinatol 2002 Jul-Aug;22(5):370-3
 Abstract
 
Transplacental passage of protease inhibitors at delivery.
 Marzolini C, Rudin C, Decosterd LA, et al.
 AIDS. 2002 Apr 12;16(6):889-893.
 Abstract
 

 
          Conference Reports, Abstracts, and Posters
 
  Lipodistrophy before Pregnancy Is a Protease Inhibitor-independent Predictor of Hypertriglyceridemia during Pregnancy in HIV-infected Pregnant Women
M Floridia,  Guaraldi, E Tamburrini,  et al
(13 CROI)
 Abstract
Nucleoside Analogues
 

          Journal Papers, Abstracts, and Commentaries

 
Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue
reverse transcriptase inhibitors in human immunodeficiency virus-infected
pregnant women.
Chappuy H, Treluyer JM, Jullien V, et al   
Antimicrob Agents Chemother. 2004 Nov;48(11):4332-6.
 Abstract

Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog
 drugs.
Poirier MC, Olivero OA, Walker DM, Walker VE. 
Toxicol Appl Pharmacol. 2004 Sep 1;199(2):151-61
 Abstract

Risk of early febrile seizure with perinatal exposure to nucleoside analogues.
Landreau-Mascaro A, Barret B, et al.
 Lancet 2002 Feb 16;359(9306):583-4
 Abstract

  
NNRTIs
 

          Journal Papers, Abstracts, and Commentaries

  Brief Report: Nonnucleoside Reverse Transcriptase Inhibitor Resistance Among
Antiretroviral-Naive HIV-Positive Pregnant Women.
Juethner SN, Williamson C, Ristig MB, et al.
J Acquir Immune Defic Syndr 2003 Feb 1;32(2):153-6
 Abstract		  

HIV Pregnancy Main Page Women Main Page  

Pregnancy: General ARV Studies